Endocrine-Related Cancer

References

1. ↵
   1. Azuara V,
   2. Perry P,
   3. Sauer S,
   4. Spivakov M,
   5. Jorgensen HF,
   6. John RM,
   7. Gouti M,
   8. Casanova M,
   9. Warnes G,
   10. Merkenschlager M
   11. et al.

   2006 Chromatin signatures of pluripotent cell lines. Nature Cell Biology 8 532–538.
2. ↵
   1. Balk SP,
   2. Ko YJ &
   3. Bubley GJ

   2003 Biology of prostate-specific antigen. Journal of Clinical Oncology 21 383–391.
3. ↵
   1. Bernstein BE,
   2. Kamal M,
   3. Lindblad-Toh K,
   4. Bekiranov S,
   5. Bailey DK,
   6. Huebert DJ,
   7. McMahon S,
   8. Karlsson EK,
   9. Kulbokas EJ III.,
   10. Gingeras TR
   11. et al.

   2005 Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120 169–181.
4. ↵
   1. Bernstein BE,
   2. Mikkelsen TS,
   3. Xie X,
   4. Kamal M,
   5. Huebert DJ,
   6. Cuff J,
   7. Fry B,
   8. Meissner A,
   9. Wernig M,
   10. Plath K
   11. et al.

   2006 A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125 315–326.
5. ↵
   1. Bhat-Nakshatri P,
   2. Wang G,
   3. Appaiah H,
   4. Luktuke N,
   5. Carroll JS,
   6. Geistlinger TR,
   7. Brown M,
   8. Badve S,
   9. Liu Y &
   10. Nakshatri H

   2008 AKT alters genome-wide estrogen receptor {α} binding and impacts estrogen signaling in breast cancer. Molecular and Cellular Biology 28 7487–7503.
6. ↵
   1. Bieda M,
   2. Xu X,
   3. Singer MA,
   4. Green R &
   5. Farnham PJ

   2006 Unbiased location analysis of E2F1-binding sites suggests a widespread role for E2F1 in the human genome. Genome Research 16 595–605.
7. ↵
   1. Bossard P &
   2. Zaret KS

   2000 Repressive and restrictive mesodermal interactions with gut endoderm: possible relation to Meckel's diverticulum. Development 127 4915–4923.
8. ↵
   1. Carroll JS,
   2. Liu XS,
   3. Brodsky AS,
   4. Li W,
   5. Meyer CA,
   6. Szary AJ,
   7. Eeckhoute J,
   8. Shao W,
   9. Hestermann EV,
   10. Geistlinger TR
   11. et al.

   2005 Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122 33–43.
9. ↵
   1. Carroll JS,
   2. Meyer CA,
   3. Song J,
   4. Li W,
   5. Geistlinger TR,
   6. Eeckhoute J,
   7. Brodsky AS,
   8. Keeton EK,
   9. Fertuck KC,
   10. Hall GF
   11. et al.

   2006 Genome-wide analysis of estrogen receptor binding sites. Nature Genetics 38 1289–1297.
10. ↵
    1. Chambeyron S &
    2. Bickmore WA

    2004 Chromatin decondensation and nuclear reorganization of the HoxB locus upon induction of transcription. Genes and Development 18 1119–1130.
11. ↵
    1. Chan CS &
    2. Song JS

    2008 CCCTC-binding factor confines the distal action of estrogen receptor. Cancer Research 68 9041–9049.
12. ↵
    1. Christensen J,
    2. Agger K,
    3. Cloos PA,
    4. Pasini D,
    5. Rose S,
    6. Sennels L,
    7. Rappsilber J,
    8. Hansen KH,
    9. Salcini AE &
    10. Helin K

    2007 RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell 128 1063–1076.
13. ↵
    1. Cicatiello L,
    2. Addeo R,
    3. Sasso A,
    4. Altucci L,
    5. Petrizzi VB,
    6. Borgo R,
    7. Cancemi M,
    8. Caporali S,
    9. Caristi S,
    10. Scafoglio C
    11. et al.

    2004 Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Molecular and Cellular Biology 24 7260–7274.
14. ↵
    1. Cirillo LA,
    2. McPherson CE,
    3. Bossard P,
    4. Stevens K,
    5. Cherian S,
    6. Shim EY,
    7. Clark KL,
    8. Burley SK &
    9. Zaret KS

    1998 Binding of the winged-helix transcription factor HNF3 to a linker histone site on the nucleosome. EMBO Journal 17 244–254.
15. ↵
    1. Dekker J

    2008 Gene regulation in the third dimension. Science 319 1793–1794.
16. ↵
    1. Demichelis F &
    2. Rubin MA

    2007 TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. Journal of Clinical Pathology 60 1185–1186.
17. ↵
    1. Deschenes J,
    2. Bourdeau V,
    3. White JH &
    4. Mader S

    2007 Regulation of GREB1 transcription by estrogen receptor alpha through a multipartite enhancer spread over 20 kb of upstream flanking sequences. Journal of Biological Chemistry 282 17335–17339.
18. ↵
    1. Eeckhoute J,
    2. Carroll JS,
    3. Geistlinger TR,
    4. Torres-Arzayus MI &
    5. Brown M

    2006 A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes and Development 20 2513–2526.
19. ↵
    1. Eeckhoute J,
    2. Keeton EK,
    3. Lupien M,
    4. Krum SA,
    5. Carroll JS &
    6. Brown M

    2007 Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Research 67 6477–6483.
20. ↵
    1. Eeckhoute J,
    2. Lupien M,
    3. Meyer C,
    4. Verzi M,
    5. Shivdasani R,
    6. Liu XS &
    7. Brown M

    2009 Cell-type selective chromatin remodeling defines the active subset of FoxA1-bound enhancers. Genome Research 19 372–380.
21. ↵
    1. Eissenberg JC,
    2. Lee MG,
    3. Schneider J,
    4. Ilvarsonn A,
    5. Shiekhattar R &
    6. Shilatifard A

    2007 The trithorax-group gene in Drosophila little imaginal discs encodes a trimethylated histone H3 Lys4 demethylase. Nature Structural & Molecular Biology 14 344–346.
22. ↵
    1. Flanagan JF,
    2. Mi LZ,
    3. Chruszcz M,
    4. Cymborowski M,
    5. Clines KL,
    6. Kim Y,
    7. Minor W,
    8. Rastinejad F &
    9. Khorasanizadeh S

    2005 Double chromodomains cooperate to recognize the methylated histone H3 tail. Nature 438 1181–1185.
23. ↵
    1. Frietze S,
    2. Lupien M,
    3. Silver PA &
    4. Brown M

    2008 CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. Cancer Research 68 301–306.
24. ↵
    1. Gao N,
    2. Zhang J,
    3. Rao MA,
    4. Case TC,
    5. Mirosevich J,
    6. Wang Y,
    7. Jin R,
    8. Gupta A,
    9. Rennie PS &
    10. Matusik RJ

    2003 The role of hepatocyte nuclear factor-3 alpha (forkhead box A1) and androgen receptor in transcriptional regulation of prostatic genes. Molecular Endocrinology 17 1484–1507.
25. ↵
    1. Giresi PG,
    2. Kim J,
    3. McDaniell RM,
    4. Iyer VR &
    5. Lieb JD

    2007 FAIRE (form, maldehyde-assisted isolation of regulatory elements) isolates active regulatory elements from human chromatin. Genome Research 17 877–885.
26. ↵
    1. Gonzalez MI &
    2. Robins DM

    2001 Oct-1 preferentially interacts with androgen receptor in a DNA-dependent manner that facilitates recruitment of SRC-1. Journal of Biological Chemistry 276 6420–6428.
27. ↵
    1. Green KA &
    2. Carroll JS

    2007 Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nature Reviews. Cancer 7 713–722.
28. ↵
    1. Gualdi R,
    2. Bossard P,
    3. Zheng M,
    4. Hamada Y,
    5. Coleman JR &
    6. Zaret KS

    1996 Hepatic specification of the gut endoderm in vitro: cell signaling and transcriptional control. Genes and Development 10 1670–1682.
29. ↵
    1. Guenther MG,
    2. Levine SS,
    3. Boyer LA,
    4. Jaenisch R &
    5. Young RA

    2007 A chromatin landmark and transcription initiation at most promoters in human cells. Cell 130 77–88.
30. ↵
    1. Habashy HO,
    2. Powe DG,
    3. Rakha EA,
    4. Ball G,
    5. Paish C,
    6. Gee J,
    7. Nicholson RI &
    8. Ellis IO

    2008 Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. European Journal of Cancer 44 1541–1551.
31. ↵
    1. Heinlein CA &
    2. Chang C

    2004 Androgen receptor in prostate cancer. Endocrine Reviews 25 276–308.
32. ↵
    1. Heintzman ND,
    2. Stuart RK,
    3. Hon G,
    4. Fu Y,
    5. Ching CW,
    6. Hawkins RD,
    7. Barrera LO,
    8. Van Calcar S,
    9. Qu C,
    10. Ching KA
    11. et al.

    2007 Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nature Genetics 39 311–318.
33. ↵
    1. Holmes KA,
    2. Song JS,
    3. Liu XS,
    4. Brown M &
    5. Carroll JS

    2008 Nkx3-1 and LEF-1 function as transcriptional inhibitors of estrogen receptor activity. Cancer Research 68 7380–7385.
34. ↵
    1. Hua S,
    2. Kallen CB,
    3. Dhar R,
    4. Baquero MT,
    5. Mason CE,
    6. Russell BA,
    7. Shah PK,
    8. Liu J,
    9. Khramtsov A,
    10. Tretiakova MS
    11. et al.

    2008 Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Molecular Systems Biology 4 188.
35. ↵
    1. Hurtado A,
    2. Holmes KA,
    3. Geistlinger TR,
    4. Hutcheson IR,
    5. Nicholson RI,
    6. Brown M,
    7. Jiang J,
    8. Howat WJ,
    9. Ali S &
    10. Carroll JS

    2008 Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456 663–666.
36. ↵
    1. Iwase S,
    2. Lan F,
    3. Bayliss P,
    4. de la Torre-Ubieta L,
    5. Huarte M,
    6. Qi HH,
    7. Whetstine JR,
    8. Bonni A,
    9. Roberts TM &
    10. Shi Y

    2007 The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell 128 1077–1088.
37. ↵
    1. Johnson DS,
    2. Mortazavi A,
    3. Myers RM &
    4. Wold B

    2007 Genome-wide mapping of in vivo protein–DNA interactions. Science 316 1497–1502.
38. ↵
    1. Klose RJ,
    2. Yan Q,
    3. Tothova Z,
    4. Yamane K,
    5. Erdjument-Bromage H,
    6. Tempst P,
    7. Gilliland DG,
    8. Zhang Y &
    9. Kaelin WG Jr.

    2007 The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell 128 889–900.
39. ↵
    1. Krum SA,
    2. Miranda-Carboni GA,
    3. Lupien M,
    4. Eeckhoute J,
    5. Carroll JS &
    6. Brown M

    2008 Unique ER{α} cistromes control cell type-specific gene regulation. Molecular Endocrinology 22 2393–2406.
40. ↵
    1. Laganiere J,
    2. Deblois G,
    3. Lefebvre C,
    4. Bataille AR,
    5. Robert F &
    6. Giguere V

    2005 Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. PNAS 102 11651–11656.
41. ↵
    1. Lapointe J,
    2. Li C,
    3. Higgins JP,
    4. van de Rijn M,
    5. Bair E,
    6. Montgomery K,
    7. Ferrari M,
    8. Egevad L,
    9. Rayford W,
    10. Bergerheim U
    11. et al.

    2004 Gene expression profiling identifies clinically relevant subtypes of prostate cancer. PNAS 101 811–816.
42. ↵
    1. Lee N,
    2. Zhang J,
    3. Klose RJ,
    4. Erdjument-Bromage H,
    5. Tempst P,
    6. Jones RS &
    7. Zhang Y

    2007 The trithorax-group protein Lid is a histone H3 trimethyl-Lys4 demethylase. Nature Structural & Molecular Biology 14 341–343.
43. ↵
    1. Lim CA,
    2. Yao F,
    3. Wong JJ,
    4. George J,
    5. Xu H,
    6. Chiu KP,
    7. Sung WK,
    8. Lipovich L,
    9. Vega VB,
    10. Chen J
    11. et al.

    2007 Genome-wide mapping of RELA(p65) binding identifies E2F1 as a transcriptional activator recruited by NF-kappaB upon TLR4 activation. Molecular Cell 27 622–635.
44. ↵
    1. Lin CY,
    2. Vega VB,
    3. Thomsen JS,
    4. Zhang T,
    5. Kong SL,
    6. Xie M,
    7. Chiu KP,
    8. Lipovich L,
    9. Barnett DH,
    10. Stossi F
    11. et al.

    2007 Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genetics 3 e87.
45. ↵
    1. Liu Y,
    2. Gao H,
    3. Marstrand TT,
    4. Strom A,
    5. Valen E,
    6. Sandelin A,
    7. Gustafsson JA &
    8. Dahlman-Wright K

    2008 The genome landscape of ER{α}- and ER{β}-binding DNA regions. PNAS 105 2604–2609.
46. ↵
    1. Lupien M,
    2. Eeckhoute J,
    3. Meyer C,
    4. Wang Q,
    5. Zhang Y,
    6. Li W,
    7. Carroll J,
    8. Liu X &
    9. Brown M

    2008 FoxA1 translates epigenetic signatures into enhancer driven lineage-specific transcription. Cell 132 958–970.
47. ↵
    1. Mikkelsen TS,
    2. Ku M,
    3. Jaffe DB,
    4. Issac B,
    5. Lieberman E,
    6. Giannoukos G,
    7. Alvarez P,
    8. Brockman W,
    9. Kim TK,
    10. Koche RP
    11. et al.

    2007 Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448 553–560.
48. ↵
    1. Mirosevich J,
    2. Gao N,
    3. Gupta A,
    4. Shappell SB,
    5. Jove R &
    6. Matusik RJ

    2006 Expression and role of Foxa proteins in prostate cancer. Prostate 66 1013–1028.
49. ↵
    1. Ng HH,
    2. Robert F,
    3. Young RA &
    4. Struhl K

    2003 Targeted recruitment of Set1 histone methylase by elongating Pol II provides a localized mark and memory of recent transcriptional activity. Molecular Cell 11 709–719.
50. ↵
    1. Perez-Stable CM,
    2. Pozas A &
    3. Roos BA

    2000 A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer. Molecular and Cellular Endocrinology 167 43–53.
51. ↵
    1. Pokholok DK,
    2. Harbison CT,
    3. Levine S,
    4. Cole M,
    5. Hannett NM,
    6. Lee TI,
    7. Bell GW,
    8. Walker K,
    9. Rolfe PA,
    10. Herbolsheimer E
    11. et al.

    2005 Genome-wide map of nucleosome acetylation and methylation in yeast. Cell 122 517–527.
52. ↵
    1. Prall OW,
    2. Rogan EM,
    3. Musgrove EA,
    4. Watts CK &
    5. Sutherland RL

    1998 c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Molecular and Cellular Biology 18 4499–4508.
53. ↵
    1. Ruthenburg AJ,
    2. Allis CD &
    3. Wysocka J

    2007 Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Molecular Cell 25 15–30.
54. ↵
    1. Sanchez R,
    2. Nguyen D,
    3. Rocha W,
    4. White JH &
    5. Mader S

    2002 Diversity in the mechanisms of gene regulation by estrogen receptors. Bioessays 24 244–254.
55. ↵
    1. Santos-Rosa H,
    2. Schneider R,
    3. Bannister AJ,
    4. Sherriff J,
    5. Bernstein BE,
    6. Emre NC,
    7. Schreiber SL,
    8. Mellor J &
    9. Kouzarides T

    2002 Active genes are tri-methylated at K4 of histone H3. Nature 419 407–411.
56. ↵
    1. Santos-Rosa H,
    2. Schneider R,
    3. Bernstein BE,
    4. Karabetsou N,
    5. Morillon A,
    6. Weise C,
    7. Schreiber SL,
    8. Mellor J &
    9. Kouzarides T

    2003 Methylation of histone H3 K4 mediates association of the Isw1p ATPase with chromatin. Molecular Cell 12 1325–1332.
57. ↵
    1. Schneider R,
    2. Bannister AJ,
    3. Myers FA,
    4. Thorne AW,
    5. Crane-Robinson C &
    6. Kouzarides T

    2004 Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. Nature Cell Biology 6 73–77.
58. ↵
    1. Schubeler D,
    2. MacAlpine DM,
    3. Scalzo D,
    4. Wirbelauer C,
    5. Kooperberg C,
    6. van Leeuwen F,
    7. Gottschling DE,
    8. O'Neill LP,
    9. Turner BM,
    10. Delrow J
    11. et al.

    2004 The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes and Development 18 1263–1271.
59. ↵
    1. Setlur SR,
    2. Mertz KD,
    3. Hoshida Y,
    4. Demichelis F,
    5. Lupien M,
    6. Perner S,
    7. Sboner A,
    8. Pawitan Y,
    9. Andren O,
    10. Johnson LA
    11. et al.

    2008 Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. Journal of the National Cancer Institute 100 815–825.
60. ↵
    1. Seward DJ,
    2. Cubberley G,
    3. Kim S,
    4. Schonewald M,
    5. Zhang L,
    6. Tripet B &
    7. Bentley DL

    2007 Demethylation of trimethylated histone H3 Lys4 in vivo by JARID1 JmjC proteins. Nature Structural & Molecular Biology 14 240–242.
61. ↵
    1. Shi Y &
    2. Whetstine JR

    2007 Dynamic regulation of histone lysine methylation by demethylases. Molecular Cell 25 1–14.
62. ↵
    1. Sims RJ III.,
    2. Chen CF,
    3. Santos-Rosa H,
    4. Kouzarides T,
    5. Patel SS &
    6. Reinberg D

    2005 Human but not yeast CHD1 binds directly and selectively to histone H3 methylated at lysine 4 via its tandem chromodomains. Journal of Biological Chemistry 280 41789–41792.
63. ↵
    1. Sorlie T,
    2. Perou CM,
    3. Tibshirani R,
    4. Aas T,
    5. Geisler S,
    6. Johnsen H,
    7. Hastie T,
    8. Eisen MB,
    9. van de Rijn M,
    10. Jeffrey SS
    11. et al.

    2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 10869–10874.
64. ↵
    1. Sorlie T,
    2. Tibshirani R,
    3. Parker J,
    4. Hastie T,
    5. Marron JS,
    6. Nobel A,
    7. Deng S,
    8. Johnsen H,
    9. Pesich R,
    10. Geisler S
    11. et al.

    2003 Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 100 8418–8423.
65. ↵
    1. Stender JD,
    2. Frasor J,
    3. Komm B,
    4. Chang KC,
    5. Kraus WL &
    6. Katzenellenbogen BS

    2007 Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Molecular Endocrinology 21 2112–2123.
66. ↵
    1. Tahiliani M,
    2. Mei P,
    3. Fang R,
    4. Leonor T,
    5. Rutenberg M,
    6. Shimizu F,
    7. Li J,
    8. Rao A &
    9. Shi Y

    2007 The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation. Nature 447 601–605.
67. ↵
    1. Thorat MA,
    2. Marchio C,
    3. Morimiya A,
    4. Savage K,
    5. Nakshatri H,
    6. Reis-Filho JS &
    7. Badve S

    2008 Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. Journal of Clinical Pathology 61 327–332.
68. ↵
    1. Valouev A,
    2. Johnson DS,
    3. Sundquist A,
    4. Medina C,
    5. Anton E,
    6. Batzoglou S,
    7. Myers RM &
    8. Sidow A

    2008 Genome-wide analysis of transcription factor binding sites based on ChIP-Seq data. Nature Methods 5 829–834.
69. ↵
    1. Wang Q,
    2. Li W,
    3. Liu XS,
    4. Carroll JS,
    5. Janne OA,
    6. Keeton EK,
    7. Chinnaiyan AM,
    8. Pienta KJ &
    9. Brown M

    2007 A hierarchical network of transcription factors governs androgen recepor dependent prostate cancer growth. Molecular Cell 27 380–392.
70. ↵
    1. Wang Q,
    2. Li W,
    3. Zhang Y,
    4. Yuan X,
    5. Xu K,
    6. Yu J,
    7. Beroukhim R,
    8. Wang H,
    9. Lupien M,
    10. Wu T
    11. et al.

    2009 Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell[in press].
71. ↵
    1. Welsh JB,
    2. Sapinoso LM,
    3. Su AI,
    4. Kern SG,
    5. Wang-Rodriguez J,
    6. Moskaluk CA,
    7. Frierson HF Jr. &
    8. Hampton GM

    2001 Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Research 61 5974–5978.
72. ↵
    1. Xi H,
    2. Shulha HP,
    3. Lin JM,
    4. Vales TR,
    5. Fu Y,
    6. Bodine DM,
    7. McKay RD,
    8. Chenoweth JG,
    9. Tesar PJ,
    10. Furey TS
    11. et al.

    2007 Identification and characterization of cell type-specific and ubiquitous chromatin regulatory structures in the human genome. PLoS Genetics 3 e136.
73. ↵
    1. Xu X,
    2. Bieda M,
    3. Jin VX,
    4. Rabinovich A,
    5. Oberley MJ,
    6. Green R &
    7. Farnham PJA

    2007 A comprehensive ChIP–chip analysis of E2F1, E2F4, and E2F6 in normal and tumor cells reveals interchangeable roles of E2F family members. Genome Research 17 1550–1561.
74. ↵
    1. Yamane K,
    2. Tateishi K,
    3. Klose RJ,
    4. Fang J,
    5. Fabrizio LA,
    6. Erdjument-Bromage H,
    7. Taylor-Papadimitriou J,
    8. Tempst P &
    9. Zhang Y

    2007 PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Molecular Cell 25 801–812.
75. ↵
    1. Yan C &
    2. Boyd DD

    2006 Histone H3 acetylation and H3 K4 methylation define distinct chromatin regions permissive for transgene expression. Molecular and Cellular Biology 26 6357–6371.
76. ↵
    1. Yu YP,
    2. Landsittel D,
    3. Jing L,
    4. Nelson J,
    5. Ren B,
    6. Liu L,
    7. McDonald C,
    8. Thomas R,
    9. Dhir R,
    10. Finkelstein S
    11. et al.

    2004 Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. Journal of Clinical Oncology 22 2790–2799.